The Pharmaceutical Journal
Vol 277 No 7483 p704
22/29 December 2007

This article
Reprint   Photocopy

  Acrobat Reader

News summary

Capecitabine in breast cancer

Adding capecitabine to trastuzumab and docetaxel increases the median time to disease progression by five months in women with advanced HER2-positive breast cancer compared with treatment without capecitabine (18.6 vs 13.6 months; hazard ratio 0.704; P=0.0295), according to results from an international study presented at the San Antonio Breast Cancer Symposium last week.